Recce Pharmaceuticals Ltd. announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), "Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer," with expiry in 2041. The Israel Patent claims relate to RECCE 327 (R327) and RECCE 529 (R529), including: Process for preparation of RECCE anti-infectives; Use of R327/R529 for the treatment of disease, particularly in the treatment of bacterial infections, viral infections, and more; Specifically, further validating RECCE anti- disinfectives from studies in burn wounds, urinary tract infections, gonorrhea, influenza, SARS-CoV-2, and more; Administration by oral, inhalation, transdermal delivery, or by injection (into the bloodstream, intramuscular, and/or intravenous); Administration may also be applied as an aerosol, gel, topical foam, or ointment (or impregnated into a dressing for application to skin or mucous membranes for transdermal or transmucosal delivery). This is the first of Recce's wholly-owned patents granted in Israel, with further Patent Cooperation Treaty Country (PCT) submissions currently under review. Israel's pharmaceuticals and biotechnology market has a reputation for high R&D spending and an impressive international reach, with world-class export numbers and a growing market value.
In 2021, Israel?s pharmaceutical market reached $5.3 billion, spending 8.3% of GDP on healthcare in 2020,1 up from 6.8% in 2000,
placing Israel as one of the fastest healthcare spending growth countries. The Central Bureau of Statistics has predicted that the elderly population in Israel will increase by 77%, accounting for 14.3% of the population by 2040. As a result, it is estimated that the Israeli pharmaceutical market will see growth on the back of the aging population due to the increasing burden of chronic diseases. Bacterial Pathogens Covered in Family 4 Specific examples of bacterial infections consist of Proteus spp, Serratia spp, Pseudomonas aeruginosa, Neisseria meningitidis, Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, coagulase-negative Staphylococcus spp, Streptococcus pyogenes, Streptococcus pneumoniae and Enterococcusspp. Viral Pathogens Covered in Family 4: Examples of viral infections include those caused by a range of viruses, including coated viruses (e.g., lipid-coated viruses) such as herpes, HIV, cytomegalovirus, and influenza. The viral infection treated and/or controlled by the method of the invention may be HSV-1, HSV-2, Varicella Zoster Virus (in the form of chicken pox or shingles), HCMV, EBV, herpes 6, herpes 7, herpes 8, and SARS-CoV-2. Other examples include influenza A,Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).